[A25-129] Asciminib (chronic myeloid leukaemia) – Addendum to Project A25-70
Last updated 20.11.2025
Project no.:
A25-129
Commission:
Commission awarded on 07.10.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with ≥ 2 tyrosine kinase inhibitors
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-129
| Project no. | Title | Status |
|---|---|---|
| A25-70 | Asciminib (chronic myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
20-11-2025 A G-BA decision was published.
G-BA documents on this decision